Nektar Therapeutics has reported durable hair regrowth in patients treated with REZPEG, and says the results set up a Phase III trial in alopecia, according to a company announcement carried by Yahoo Finance.

The disclosure marks the most concrete step yet for REZPEG as a potential treatment for hair loss. Nektar positioned the durability of regrowth — persistence of hair regrowth after treatment — as the central finding of the data release, and framed the dataset as sufficient to advance the program into late-stage, Phase III development.

What does the announcement actually establish?

The headline claim rests on two elements: the regrowth observed during treatment was durable, and the evidence package is strong enough to justify a registrational program. Durable response is the metric that has historically separated mechanistically interesting alopecia candidates from therapies that can hold up in pivotal testing, because hair regrowth that reverses after discontinuation carries limited clinical value.

No specific effect sizes, patient counts, or trial duration figures accompanied the initial headline-level disclosure. Derm Field will report the full parameter set — including scalp coverage scores and responder thresholds — when Nektar publishes the complete dataset or presents it at a medical meeting.

Why alopecia is the target

Alopecia areata is an autoimmune hair-loss disorder in which T-cell-mediated attack on the hair follicle produces patchy to complete scalp and body hair loss. The condition sits squarely in the dermatology treatment landscape that REZPEG is being developed to address.

The REZPEG program is notable for reaching this stage in an indication where the approved biologic toolkit remains narrow. A durable-response profile, if confirmed in controlled late-stage testing, would give prescribers an additional mechanistic option beyond the existing standard of care.

What comes next

According to the company statement, the data clear the path to a Phase III trial. The transition from these results into a pivotal alopecia program will be the inflection point to watch: late-stage trials will need to reproduce the durability signal in larger, controlled cohorts under registrational endpoints.

For dermatologists, the immediate takeaway is procedural rather than practice-changing — no formulation, dosing schedule, or eligibility profile is yet available. The durability finding and the Phase III commitment, however, signal that a new mechanism for autoimmune hair loss is advancing toward the pivotal stage.